Nexvet Biopharma's Grant

Nexvet Biopharma raised a round of funding on August 28, 2013. Investors include Commercialisation Australia.

Nexvet develops monoclonal antibody therapies for companion animals (e.g. dogs and cats) using its proprietary PETisation platform technology, which uniquely produces therapies 100% customized to targ…

Articles about Nexvet Biopharma's Grant: